65,437 trials
Arthroplasty, Replacement, Hip
Primary: Identification of the Random Initials by the Reviewing Orthopaedic Surgeons — 209; 296 number of correctly identified initals
Stroke, Acute · Stroke · Hemiparesis
Primary: Maximum Voluntary Finger Extension Angle (a Measure of Hand Impairment) — -11.6; -43.4 degrees
Dysmenorrhea
Primary: Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose — 17.38; 16.49 Score on a Scale — p=0.043
Chronic Pain · Osteoarthritis · Low Back Pain
Primary: Time From the Initial Day of Application in Double-Blind Period to Withdrawal Because of Insufficient Analgesic Efficacy — NA; NA Days — p=0.0846
Inflammation · Familial Mediterranean Fever · Still's Disease, Adult-Onset
Primary: Mean Change in Daily Scores — -3.09 units on a scale
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR). — 0; 1 participants
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 92 or Early Withdrawal — 82.1; 84.4; -23.6; -26.9 Units on scale
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment — -58.9; -58.7 Percentage Change
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Proportion of Successes (Patients Alive and Progression-free) — 15.2; 26.7; 10 percentage of participants
Cocaine Use Disorders
Primary: Subjective Craving of Cocaine — 2.47; 0.90; 1.19; 1.06 units on a scale
Hepatitis D
Primary: Histological Response at 3 Years — 6 participants
Hepatitis C · HIV
Primary: Boceprevir AUC Pharmacokinetics — 4601 ng*hr/mL
Influenza
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms After Vaccination — 45; 55; 1; 1 Participants
Cardiovascular Disease · Bleeding
Primary: Platelet Aggegation (Arachiodonic Acid)Using a PAP-8E (BioData Corp.) — 79.5; 0; 5.5; 8 percent
Meningitis · Meningococcal Infection
Primary: Percentages of Subjects With At Least One Severe Systemic Reaction After Any Vaccination — 16; 13 Percentages of subjects